Regulatory T cells in immune-mediated renal disease

Nephrology

Volumn 21, Issue 2, 2016, Pages 86-96

  Ghali, Joanna R ^a,b   Wang, Yuan Min ^c   Holdsworth, Stephen R ^a,b   Kitching, A Richard ^a,b  

^a MONASH UNIVERSITY   (Australia)

^b MONASH MEDICAL CENTRE   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

acute kidney injury; anti cytoplasmic neutrophil antibody associated vasculitis; anti glomerular basement membrane disease; lupus erythematosus; regulatory T cell; systemic

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; GLUCOCORTICOID; IMMUNOGLOBULIN G; INTERLEUKIN 10; INTERLEUKIN 2; RITUXIMAB; STAT3 PROTEIN;

ACUTE KIDNEY FAILURE; ANCA ASSOCIATED VASCULITIS; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; AUTOIMMUNITY; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CELL THERAPY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG RESPONSE; FOXP3 GENE; GENE; GLOMERULONEPHRITIS; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; INNATE IMMUNITY; LYMPHOCYTE COUNT; LYMPHOCYTE PROLIFERATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEINURIA; REGULATORY T LYMPHOCYTE; SYSTEMIC LUPUS ERYTHEMATOSUS; UPREGULATION; ANIMAL; AUTOIMMUNE DISEASES; DISEASE MODEL; IMMUNOLOGY; IMMUNOTHERAPY; KIDNEY DISEASES; LYMPHOCYTE ACTIVATION; METABOLISM; MOUSE; PATHOLOGY; PHENOTYPE; PROCEDURES; TRANSPLANTATION;

ANIMALS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; DISEASE MODELS, ANIMAL; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; KIDNEY DISEASES; LYMPHOCYTE ACTIVATION; MICE; PHENOTYPE; T-LYMPHOCYTES, REGULATORY;

EID: 84955609441     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/nep.12574     Document Type: Article

References (125)

1. Schmetterer KG, Neunkirchner A, Pickl WF,. Naturally occurring regulatory T cells: markers, mechanisms, and manipulation. FASEB J. 2012; 26: 2253-2276.
2. Grant CR, Liberal R, Mieli-Vergani G, et al. Regulatory T-cells in autoimmune diseases: challenges, controversies and-yet-unanswered questions. Autoimmun. Rev. 2015; 14: 105-116.
3. Marie JC, Letterio JJ, Gavin M, et al. TGF-beta1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells. J. Exp. Med. 2005; 201: 1061-1067.
4. Chen W, Jin W, Hardegen N, et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J. Exp. Med. 2003; 198: 1875-1886.
5. Tran DQ,. TGF-beta: the sword, the wand, and the shield of FOXP3(+) regulatory T cells. J Mol Cell Biol. 2012; 4: 29-37.
6. Dieckmann D, Plottner H, Berchtold S, et al. Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood. J. Exp. Med. 2001; 193: 1303-1310.
7. Annacker O, Pimenta-Araujo R, Burlen-Defranoux O, et al. CD25+ CD4+ T cells regulate the expansion of peripheral CD4 T cells through the production of IL-10. J. Immunol. 2001; 166: 3008-3018.
8. Collison LW, Pillai MR, Chaturvedi V, et al. Regulatory T cell suppression is potentiated by target T cells in a cell contact, IL-35- and IL-10-dependent manner. J. Immunol. 2009; 182: 6121-6128.
9. Collison LW, Workman CJ, Kuo TT, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 2007; 450: 566-569.
10. Bardel E, Larousserie F, Charlot-Rabiega P, et al. Human CD4+ CD25+ Foxp3+ regulatory T cells do not constitutively express IL-35. J. Immunol. 2008; 181: 6898-6905.
11. Tao Q, Pan Y, Wang Y, et al. Regulatory T cells-derived IL-35 promotes the growth of adult acute myeloid leukemia blasts. Int. J. Cancer 2015; Apr 11. doi: 10.1002/ijc.29563. [Epub ahead of print].
12. Wing K, Onishi Y, Prieto-Martin P, et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science 2008; 322: 271-275.
13. Teft WA, Kirchhof MG, Madrenas J,. A molecular perspective of CTLA-4 function. Annu. Rev. Immunol. 2006; 24: 65-97.
14. McHugh RS, Whitters MJ, Piccirillo CA, et al. CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity 2002; 16: 311-323.
15. Shevach EM, Stephens GL,. The GITR-GITRL interaction: co-stimulation or contrasuppression of regulatory activity? Nat. Rev. Immunol. 2006; 6: 613-618.
16. Borsellino G, Kleinewietfeld M, Di Mitri D, et al. Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 2007; 110: 1225-1232.
17. Deaglio S, Dwyer KM, Gao W, et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J. Exp. Med. 2007; 204: 1257-1265.
18. Sakaguchi S, Sakaguchi N, Asano M, et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 1995; 155: 1151-1164.
19. Thornton AM, Shevach EM,. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J. Exp. Med. 1998; 188: 287-296.
20. Baecher-Allan C, Brown JA, Freeman GJ, et al. CD4+CD25high regulatory cells in human peripheral blood. J. Immunol. 2001; 167: 1245-1253.
21. Liu W, Putnam AL, Xu-Yu Z, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J. Exp. Med. 2006; 203: 1701-1711.
22. Hartigan-O'Connor DJ, Poon C, Sinclair E, et al. Human CD4+ regulatory T cells express lower levels of the IL-7 receptor alpha chain (CD127), allowing consistent identification and sorting of live cells. J. Immunol. Methods 2007; 319: 41-52.
23. Ghiringhelli F, Menard C, Terme M, et al. CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J. Exp. Med. 2005; 202: 1075-1085.
24. Cavassani KA, Campanelli AP, Moreira AP, et al. Systemic and local characterization of regulatory T cells in a chronic fungal infection in humans. J. Immunol. 2006; 177: 5811-5818.
25. Nakamura K, Kitani A, Strober W,. Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J. Exp. Med. 2001; 194: 629-644.
26. Okazaki T, Iwai Y, Honjo T,. New regulatory co-receptors: inducible co-stimulator and PD-1. Curr. Opin. Immunol. 2002; 14: 779-782.
27. Lohning M, Hutloff A, Kallinich T, et al. Expression of ICOS in vivo defines CD4+ effector T cells with high inflammatory potential and a strong bias for secretion of interleukin 10. J. Exp. Med. 2003; 197: 181-193.
28. Ito T, Hanabuchi S, Wang YH, et al. Two functional subsets of FOXP3+ regulatory T cells in human thymus and periphery. Immunity 2008; 28: 870-880.
29. Hori S, Nomura T, Sakaguchi S,. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299: 1057-1061.
30. Fontenot JD, Gavin MA, Rudensky AY,. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat. Immunol. 2003; 4: 330-336.
31. Williams LM, Rudensky AY,. Maintenance of the Foxp3-dependent developmental program in mature regulatory T cells requires continued expression of Foxp3. Nat. Immunol. 2007; 8: 277-284.
32. Gavin MA, Torgerson TR, Houston E, et al. Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development. Proc. Natl. Acad. Sci. U.S.A. 2006; 103: 6659-6664.
33. Komatsu N, Hori S,. Full restoration of peripheral Foxp3+ regulatory T cell pool by radioresistant host cells in scurfy bone marrow chimeras. Proc. Natl. Acad. Sci. U.S.A. 2007; 104: 8959-8964.
34. Salama AD, Chaudhry AN, Ryan JJ, et al. In Goodpasture's disease, CD4(+) T cells escape thymic deletion and are reactive with the autoantigen alpha3(IV)NC1. J. Am. Soc. Nephrol. 2001; 12: 1908-1915.
35. Salama AD, Chaudhry AN, Holthaus KA, et al. Regulation by CD25+ lymphocytes of autoantigen-specific T-cell responses in Goodpasture's (anti-GBM) disease. Kidney Int. 2003; 64: 1685-1694.
36. Cairns LS, Phelps RG, Bowie L, et al. The fine specificity and cytokine profile of T-helper cells responsive to the alpha3 chain of type IV collagen in Goodpasture's disease. J. Am. Soc. Nephrol. 2003; 14: 2801-2812.
37. Odobasic D, Ghali JR, O'sullivan KM, et al. Glomerulonephritis induced by heterologous anti-GBM globulin as a planted foreign antigen. Curr Protoc Immunol. 2014; 106: 15 26 1-20.
38. Ooi JD, Snelgrove SL, Engel DR, et al. Endogenous foxp3(+) T-regulatory cells suppress anti-glomerular basement membrane nephritis. Kidney Int. 2011; 79: 977-986.
39. Paust HJ, Ostmann A, Erhardt A, et al. Regulatory T cells control the Th1 immune response in murine crescentic glomerulonephritis. Kidney Int. 2011; 80: 154-164.
40. Wolf D, Hochegger K, Wolf AM, et al. CD4+CD25+ regulatory T cells inhibit experimental anti-glomerular basement membrane glomerulonephritis in mice. J. Am. Soc. Nephrol. 2005; 16: 1360-1370.
41. Forster R, Davalos-Misslitz AC, Rot A,. CCR7 and its ligands: balancing immunity and tolerance. Nat. Rev. Immunol. 2008; 8: 362-371.
42. Turner JE, Paust HJ, Steinmetz OM, et al. CCR6 recruits regulatory T cells and Th17 cells to the kidney in glomerulonephritis. J. Am. Soc. Nephrol. 2010; 21: 974-985.
43. Ostmann A, Paust HJ, Panzer U, et al. Regulatory T cell-derived IL-10 ameliorates crescentic GN. J. Am. Soc. Nephrol. 2013; 24: 930-942.
44. Kitching AR, Tipping PG, Timoshanko JR, et al. Endogenous interleukin-10 regulates Th1 responses that induce crescentic glomerulonephritis. Kidney Int. 2000; 57: 518-525.
45. Kluger MA, Luig M, Wegscheid C, et al. Stat3 programs Th17-specific regulatory T cells to control GN. J. Am. Soc. Nephrol. 2014; 25: 1291-1302.
46. Steinmetz OM, Summers SA, Gan PY, et al. The Th17-defining transcription factor RORgammat promotes glomerulonephritis. J. Am. Soc. Nephrol. 2011; 22: 472-483.
47. Paust HJ, Turner JE, Steinmetz OM, et al. The IL-23/Th17 axis contributes to renal injury in experimental glomerulonephritis. J. Am. Soc. Nephrol. 2009; 20: 969-979.
48. Rimbert M, Hamidou M, Braudeau C, et al. Decreased numbers of blood dendritic cells and defective function of regulatory T cells in antineutrophil cytoplasmic antibody-associated vasculitis. PLoS ONE 2011; 6: e18734.
49. Free ME, Bunch DO, McGregor JA, et al. Patients with antineutrophil cytoplasmic antibody-associated vasculitis have defective Treg cell function exacerbated by the presence of a suppression-resistant effector cell population. Arthritis Rheum. 2013; 65: 1922-1933.
50. Klapa S, Mueller A, Csernok E, et al. Lower numbers of FoxP3 and CCR4 co-expressing cells in an elevated subpopulation of CD4+CD25high regulatory T cells from Wegener's granulomatosis. Clin. Exp. Rheumatol. 2010; 28: 72-80.
51. Abdulahad WH, Stegeman CA, van der Geld YM, et al. Functional defect of circulating regulatory CD4+ T cells in patients with Wegener's granulomatosis in remission. Arthritis Rheum. 2007; 56: 2080-2091.
52. Morgan MD, Day CJ, Piper KP, et al. Patients with Wegener's granulomatosis demonstrate a relative deficiency and functional impairment of T-regulatory cells. Immunology 2010; 130: 64-73.
53. Chavele KM, Shukla D, Keteepe-Arachi T, et al. Regulation of myeloperoxidase-specific T cell responses during disease remission in antineutrophil cytoplasmic antibody-associated vasculitis: the role of Treg cells and tryptophan degradation. Arthritis Rheum. 2010; 62: 1539-1548.
54. Abdulahad WH, van der Geld YM, Stegeman CA, et al. Persistent expansion of CD4+ effector memory T cells in Wegener's granulomatosis. Kidney Int. 2006; 70: 938-947.
55. Yoshimura J, Fukami K, Koike K, et al. Interstitial Foxp3-positive T cells may predict renal survival in patients with myeroperoxidase anti-neutrophil cytoplasmic antibody-associated glomerulonephritis. Clin. Exp. Pharmacol. Physiol. 2010; 37: 879-883.
56. O'sullivan KM, Lo C, Summers SA, et al. Renal participation of myeloperoxidase in anti-neutrophil cytoplasmic antibody associated glomerulonephritis. Kidney Int. 2015; Jul 15. doi: 10.1038/ki.2015.202. [Epub ahead of print].
57. Aschenbrenner K, D'Cruz LM, Vollmann EH, et al. Selection of Foxp3+ regulatory T cells specific for self antigen expressed and presented by Aire+ medullary thymic epithelial cells. Nat. Immunol. 2007; 8: 351-358.
58. Mathis D, Benoist C,. Aire. Annu. Rev. Immunol. 2009; 27: 287-312.
59. Lin W, Haribhai D, Relland LM, et al. Regulatory T cell development in the absence of functional Foxp3. Nat. Immunol. 2007; 8: 359-368.
60. Tan DS, Gan PY, O'sullivan KM, et al. Thymic deletion and regulatory T cells prevent antimyeloperoxidase GN. J. Am. Soc. Nephrol. 2013; 24: 573-585.
61. Ruth AJ, Kitching AR, Kwan RY, et al. Anti-neutrophil cytoplasmic antibodies and effector CD4+ cells play nonredundant roles in anti-myeloperoxidase crescentic glomerulonephritis. J. Am. Soc. Nephrol. 2006; 17: 1940-1949.
62. Ooi JD, Gan PY, Odobasic D, et al. T cell mediated autoimmune glomerular disease in mice. Curr Protoc Immunol. 2014; 107: 15 27 1-19.
63. Neumann I, Birck R, Newman M, et al. SCG/Kinjoh mice: a model of ANCA-associated crescentic glomerulonephritis with immune deposits. Kidney Int. 2003; 64: 140-148.
64. Hirahashi J, Kawahata K, Arita M, et al. Immunomodulation with eicosapentaenoic acid supports the treatment of autoimmune small-vessel vasculitis. Sci Rep. 2014; 4: 6406. doi: 10.1038/srep06406.
65. Xing Q, Wang B, Su H, et al. Elevated Th17 cells are accompanied by FoxP3+ Treg cells decrease in patients with lupus nephritis. Rheumatol. Int. 2012; 32: 949-958.
66. Barath S, Aleksza M, Tarr T, et al. Measurement of natural (CD4+CD25high) and inducible (CD4+IL-10+) regulatory T cells in patients with systemic lupus erythematosus. Lupus 2007; 16: 489-496.
67. Yang J, Chu Y, Yang X, et al. Th17 and natural Treg cell population dynamics in systemic lupus erythematosus. Arthritis Rheum. 2009; 60: 1472-1483.
68. Valencia X, Yarboro C, Illei G, et al. Deficient CD4+CD25high T regulatory cell function in patients with active systemic lupus erythematosus. J. Immunol. 2007; 178: 2579-2588.
69. Barreto M, Ferreira RC, Lourenco L, et al. Low frequency of CD4+CD25+ Treg in SLE patients: a heritable trait associated with CTLA4 and TGFbeta gene variants. BMC Immunol. 2009; 10: 5.
70. Miyara M, Amoura Z, Parizot C, et al. Global natural regulatory T cell depletion in active systemic lupus erythematosus. J. Immunol. 2005; 175: 8392-8400.
71. Yates J, Whittington A, Mitchell P, et al. Natural regulatory T cells: number and function are normal in the majority of patients with lupus nephritis. Clin. Exp. Immunol. 2008; 153: 44-55.
72. Wang G, Lai FM, Tam LS, et al. Urinary FOXP3 mRNA in patients with lupus nephritis-relation with disease activity and treatment response. Rheumatology (Oxford) 2009; 48: 755-760.
73. Iikuni N, Lourenco EV, Hahn BH, et al. Cutting edge: regulatory T cells directly suppress B cells in systemic lupus erythematosus. J. Immunol. 2009; 183: 1518-1522.
74. Sfikakis PP, Souliotis VL, Fragiadaki KG, et al. Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis. Clin. Immunol. 2007; 123: 66-73.
75. Sfikakis PP, Boletis JN, Lionaki S, et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum. 2005; 52: 501-513.
76. Andrews BS, Eisenberg RA, Theofilopoulos AN, et al. Spontaneous murine lupus-like syndromes. Clinical and immunopathological manifestations in several strains. J. Exp. Med. 1978; 148: 1198-1215.
77. Via CS, Shearer GM,. Functional heterogeneity of L3T4+ T cells in MRL-lpr/lpr mice. L3T4+ T cells suppress major histocompatibility complex-self-restricted L3T4+ T helper cell function in association with autoimmunity. J. Exp. Med. 1988; 168: 2165-2181.
78. Abe J, Ueha S, Suzuki J, et al. Increased Foxp3(+) CD4(+) regulatory T cells with intact suppressive activity but altered cellular localization in murine lupus. Am. J. Pathol. 2008; 173: 1682-1692.
79. Scalapino KJ, Daikh DI,. Suppression of glomerulonephritis in NZB/NZW lupus prone mice by adoptive transfer of ex vivo expanded regulatory T cells. PLoS ONE 2009; 4: e6031.
80. Weigert O, von Spee C, Undeutsch R, et al. CD4+Foxp3+ regulatory T cells prolong drug-induced disease remission in (NZBxNZW) F1 lupus mice. Arthritis Res. Ther. 2013; 15: R35.
81. Monk CR, Spachidou M, Rovis F, et al. MRL/Mp CD4+,CD25- T cells show reduced sensitivity to suppression by CD4+,CD25+ regulatory T cells in vitro: a novel defect of T cell regulation in systemic lupus erythematosus. Arthritis Rheum. 2005; 52: 1180-1184.
82. Liu Y, Liu A, Iikuni N, et al. Regulatory CD4+ T cells promote B cell anergy in murine lupus. J. Immunol. 2014; 192: 4069-4073.
83. Singh RR, Kumar V, Ebling FM, et al. T cell determinants from autoantibodies to DNA can upregulate autoimmunity in murine systemic lupus erythematosus. J. Exp. Med. 1995; 181: 2017-2027.
84. Hahn BH, Singh RR, Wong WK, et al. Treatment with a consensus peptide based on amino acid sequences in autoantibodies prevents T cell activation by autoantigens and delays disease onset in murine lupus. Arthritis Rheum. 2001; 44: 432-441.
85. La Cava A, Ebling FM, Hahn BH,. Ig-reactive CD4+CD25+ T cells from tolerized (New Zealand Black × New Zealand White) F1 mice suppress in vitro production of antibodies to DNA. J. Immunol. 2004; 173: 3542-3548.
86. Lourenco EV, Procaccini C, Ferrera F, et al. Modulation of p38 MAPK activity in regulatory T cells after tolerance with anti-DNA Ig peptide in (NZB × NZW)F1 lupus mice. J. Immunol. 2009; 182: 7415-7421.
87. Burne MJ, Daniels F, El Ghandour A, et al. Identification of the CD4(+) T cell as a major pathogenic factor in ischemic acute renal failure. J. Clin. Invest. 2001; 108: 1283-1290.
88. Ascon DB, Lopez-Briones S, Liu M, et al. Phenotypic and functional characterization of kidney-infiltrating lymphocytes in renal ischemia reperfusion injury. J. Immunol. 2006; 177: 3380-3387.
89. Gandolfo MT, Jang HR, Bagnasco SM, et al. Foxp3+ regulatory T cells participate in repair of ischemic acute kidney injury. Kidney Int. 2009; 76: 717-729.
90. Jang HR, Gandolfo MT, Ko GJ, et al. The effect of murine anti-thymocyte globulin on experimental kidney warm ischemia-reperfusion injury in mice. Transpl. Immunol. 2009; 22: 44-54.
91. Gandolfo MT, Jang HR, Bagnasco SM, et al. Mycophenolate mofetil modifies kidney tubular injury and Foxp3+ regulatory T cell trafficking during recovery from experimental ischemia-reperfusion. Transpl. Immunol. 2010; 23: 45-52.
92. Monteiro RM, Camara NO, Rodrigues MM, et al. A role for regulatory T cells in renal acute kidney injury. Transpl. Immunol. 2009; 21: 50-55.
93. Jun C, Ke W, Qingshu L, et al. Protective effect of CD4(+)CD25(high)CD127(low) regulatory T cells in renal ischemia-reperfusion injury. Cell. Immunol. 2014; 289: 106-111.
94. Kinsey GR, Sharma R, Huang L, et al. Regulatory T cells suppress innate immunity in kidney ischemia-reperfusion injury. J. Am. Soc. Nephrol. 2009; 20: 1744-1753.
95. Lai LW, Yong KC, Lien YH,. Pharmacologic recruitment of regulatory T cells as a therapy for ischemic acute kidney injury. Kidney Int. 2012; 81: 983-992.
96. Jaworska K, Ratajczak J, Huang L, et al. Both PD-1 ligands protect the kidney from ischemia reperfusion injury. J. Immunol. 2015; 194: 325-333.
97. Kim MG, Lee SY, Ko YS, et al. CD4+ CD25+ regulatory T cells partially mediate the beneficial effects of FTY720, a sphingosine-1-phosphate analogue, during ischaemia/reperfusion-induced acute kidney injury. Nephrol. Dial. Transplant. 2011; 26: 111-124.
98. Hu J, Zhang L, Wang N, et al. Mesenchymal stem cells attenuate ischemic acute kidney injury by inducing regulatory T cells through splenocyte interactions. Kidney Int. 2013; 84: 521-531.
99. Kim MG, Koo TY, Yan JJ, et al. IL-2/anti-IL-2 complex attenuates renal ischemia-reperfusion injury through expansion of regulatory T cells. J. Am. Soc. Nephrol. 2013; 24: 1529-1536.
100. Liu M, Chien CC, Burne-Taney M, et al. A pathophysiologic role for T lymphocytes in murine acute cisplatin nephrotoxicity. J. Am. Soc. Nephrol. 2006; 17: 765-774.
101. Deng J, Kohda Y, Chiao H, et al. Interleukin-10 inhibits ischemic and cisplatin-induced acute renal injury. Kidney Int. 2001; 60: 2118-2128.
102. Lee H, Nho D, Chung HS, et al. CD4+CD25+ regulatory T cells attenuate cisplatin-induced nephrotoxicity in mice. Kidney Int. 2010; 78: 1100-1109.
103. Kim H, Lee G, Park S, et al. Bee venom mitigates cisplatin-induced nephrotoxicity by regulating CD4(+)CD25(+)Foxp3(+) regulatory T cells in mice. Evid. Based Complement. Alternat. Med. 2013; 2013: 879845.
104. Alikhan MA, Summers SA, Gan PY, et al. Endogenous TLR9 regulates acute kidney injury by promoting regulatory T cell recruitment. J. Am. Soc. Nephrol. 2015; Jun 26. pii: ASN.2014090927. [Epub ahead of print].
105. Yildiz B, Cetin N, Kural N, et al. CD19 + CD23+ B cells, CD4 + CD25+ T cells, E-selectin and interleukin-12 levels in children with steroid sensitive nephrotic syndrome. Ital J Pediatr. 2013; 39: 42.
106. Araya C, Diaz L, Wasserfall C, et al. T regulatory cell function in idiopathic minimal lesion nephrotic syndrome. Pediatr. Nephrol. 2009; 24: 1691-1698.
107. Mahajan D, Wang Y, Qin X, et al. CD4+CD25+ regulatory T cells protect against injury in an innate murine model of chronic kidney disease. J. Am. Soc. Nephrol. 2006; 17: 2731-2741.
108. Wang YM, Zhang GY, Wang Y, et al. Foxp3-transduced polyclonal regulatory T cells protect against chronic renal injury from adriamycin. J. Am. Soc. Nephrol. 2006; 17: 697-706.
109. Wang Y, Wang Y, Wang Y, et al. Regulatory T cells require renal antigen recognition through the TCR to protect against injury in nephritis. Int J Clin Exp Pathol. 2014; 7: 38-47.
110. Wang YM, McRae JL, Robson SC, et al. Regulatory T cells participate in CD39-mediated protection from renal injury. Eur. J. Immunol. 2012; 42: 2441-2451.
111. Polhill T, Zhang GY, Hu M, et al. IL-2/IL-2Ab complexes induce regulatory T cell expansion and protect against proteinuric CKD. J. Am. Soc. Nephrol. 2012; 23: 1303-1308.
112. Le Berre L, Bruneau S, Naulet J, et al. Induction of T regulatory cells attenuates idiopathic nephrotic syndrome. J. Am. Soc. Nephrol. 2009; 20: 57-67.
113. Zhou X, Bailey-Bucktrout SL, Jeker LT, et al. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat. Immunol. 2009; 10: 1000-1007.
114. Komatsu N, Okamoto K, Sawa S, et al. Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis. Nat. Med. 2014; 20: 62-68.
115. Beres A, Komorowski R, Mihara M, et al. Instability of Foxp3 expression limits the ability of induced regulatory T cells to mitigate graft versus host disease. Clin. Cancer Res. 2011; 17: 3969-3983.
116. Rossetti M, Spreafico R, Saidin S, et al. Ex vivo-expanded but not in vitro-induced human regulatory T cells are candidates for cell therapy in autoimmune diseases thanks to stable demethylation of the FOXP3 regulatory T cell-specific demethylated region. J. Immunol. 2015; 194: 113-124.
117. Lal G, Zhang N, van der Touw W, et al. Epigenetic regulation of Foxp3 expression in regulatory T cells by DNA methylation. J. Immunol. 2009; 182: 259-273.
118. Lal G, Bromberg JS,. Epigenetic mechanisms of regulation of Foxp3 expression. Blood 2009; 114: 3727-3735.
119. Floess S, Freyer J, Siewert C, et al. Epigenetic control of the Foxp3 locus in regulatory T cells. PLoS Biol. 2007; 5: e38.
120. Lu L, Lan Q, Li Z, et al. Critical role of all-trans retinoic acid in stabilizing human natural regulatory T cells under inflammatory conditions. Proc. Natl. Acad. Sci. U.S.A. 2014; 111: E3432-3440.
121. Lu L, Ma J, Li Z, et al. All-trans retinoic acid promotes TGF-beta-induced Tregs via histone modification but not DNA demethylation on Foxp3 gene locus. PLoS ONE 2011; 6: e24590.
122. Golovina TN, Mikheeva T, Brusko TM, et al. Retinoic acid and rapamycin differentially affect and synergistically promote the ex vivo expansion of natural human T regulatory cells. PLoS ONE 2011; 6: e15868.
123. Canavan JB, Scotta C, Vossenkamper A, et al. Developing in vitro expanded CD45RA+ regulatory T cells as an adoptive cell therapy for Crohn's disease. Gut 2015; 0: 1-11. doi: 10.1136/gutjnl-2014-306919
124. Scotta C, Esposito M, Fazekasova H, et al. Differential effects of rapamycin and retinoic acid on expansion, stability and suppressive qualities of human CD4(+)CD25(+)FOXP3(+) T regulatory cell subpopulations. Haematologica 2013; 98: 1291-1299.
125. Putnam AL, Safinia N, Medvec A, et al. Clinical grade manufacturing of human alloantigen-reactive regulatory T cells for use in transplantation. Am. J. Transplant. 2013; 13: 3010-3020.